• +1-646-491-9876
    • +91-20-67278686

    Search

    Sarcopenia Pipeline Review H2 2017

    Sarcopenia Pipeline Review H2 2017

    • Report Code ID: RW0001884135
    • Category Pharmaceuticals
    • No. of Pages 60
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Sarcopenia - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2017, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

    Sarcopenia is defined as the loss of mass and muscular function with age. Symptoms include obesity, difficulty walking or moving about, lack of strength and respiratory problems. Treatment includes medications and hormone replacement therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Sarcopenia - Overview
    Sarcopenia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Sarcopenia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Sarcopenia - Companies Involved in Therapeutics Development
    Amgen Inc
    Biophytis SAS
    GlaxoSmithKline Plc
    Immusoft Corp
    MYOS RENS Technology Inc
    Neurotune AG
    Novartis AG
    Regeneron Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Teijin Pharma Ltd
    Sarcopenia - Drug Profiles
    ARM-210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATA-842 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVGN-7 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bimagrumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIO-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Sarcopenia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEP-28 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-1654 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Proteins for Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Sarcopenia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TEISARM-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trevogrumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sarcopenia - Dormant Projects
    Sarcopenia - Discontinued Products
    Sarcopenia - Product Development Milestones
    Featured News & Press Releases
    May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
    May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
    Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
    Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona
    Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients
    Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia
    Nov 29, 2016: BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile
    Nov 22, 2016: BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
    Nov 15, 2016: BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting
    Sep 22, 2016: BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase
    Aug 26, 2016: BIOPHYTIS: enrollment of the first subjects in the pharmacokinetics study on Sarcopenia
    Jul 25, 2016: BIOPHYTIS Receives Belgian Regulatory Authorization to Start Sarconeos Pharmacokinetics Study in Elderly Healthy Volunteers (SARA-PK)
    Apr 12, 2016: BIOPHYTIS to Present Key Research Findings on Company Lead Compound at Upcoming Scientific Conferences
    Mar 11, 2016: BIOPHYTIS Receives positive Scientific Advice on SARCOB BIO101 Clinical Development Plan from Belgian Regulatory Authority
    Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Sarcopenia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Sarcopenia - Pipeline by Amgen Inc, H2 2017
    Sarcopenia - Pipeline by Biophytis SAS, H2 2017
    Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2017
    Sarcopenia - Pipeline by Immusoft Corp, H2 2017
    Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2017
    Sarcopenia - Pipeline by Neurotune AG, H2 2017
    Sarcopenia - Pipeline by Novartis AG, H2 2017
    Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
    Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
    Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2017
    Sarcopenia - Dormant Projects, H2 2017
    Sarcopenia - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Sarcopenia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Targets, H2 2017
    Number of Products by Stage and Targets, H2 2017
    Number of Products by Mechanism of Actions, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Amgen Inc
    Biophytis SAS
    GlaxoSmithKline Plc
    Immusoft Corp
    MYOS RENS Technology Inc
    Neurotune AG
    Novartis AG
    Regeneron Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Teijin Pharma Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//sarcopenia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//sarcopenia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//sarcopenia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments